Fig. 1 · Structure

Documents & Downloads

Luteoloside

Cat. No. A12085 CAS 5373-11-5
Cynaroside is a flavone, a flavonoid-like chemical compound. It is a 7-O-glucoside of luteolin and can be found in dandelion coffee, in Ferula varia and F. foetida in Campanula persicifolia and C. rotundifolia, in the bamboo Phyllostachys nigra and in Cynara scolymus (artichoke).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
B16-4A5 IC50 > 100 μM Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis [PMID: 25987378]
CCRF-CEM IC50 > 10 μg/mL Cytotoxicity against human CEM cells after 3 days by MTT assay [PMID: 11421746]
H9 IC50 25 μM Cytotoxicity against human H9 cells after 3 days [PMID: 8158164]
H9 EC50 7 μM Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay [PMID: 8158164]
H9c2 EC50 5.04 μM Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 20932762]
HeLa S3 IC50 > 10 μM Cytotoxicity against human HeLa S3 cells assessed as cell viability incubated for 48 hrs by microscopic analysis [PMID: 35704432]
HepG2 IC50 20.8 μM Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 24974349]
HL-60 IC50 > 10 μg/mL Cytotoxicity against human HL60 cells after 3 days by MTT assay [PMID: 11421746]
Huh-7 CC50 > 50 μM Cytotoxicity against human Huh7.5.1 cells by MTT assay [PMID: 22445328]
MDCK CC50 > 1116 μM Cytotoxicity against MDCK cells by MTT assay [PMID: 18640042]
RAW264.7 CC50 > 100 μM Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay [PMID: 33667099]
RAW264.7 IC50 > 20 μM Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method [PMID: 19778086]
RAW264.7 IC50 6.1 μM Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA [PMID: 31747281]
RAW264.7 IC50 8.3 μM Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method [PMID: 25176187]
RAW264.7 IC50 87.5 μM Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay [PMID: 33667099]
RD EC50 0.43 mM Antiviral activity against EV71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 48 hrs by MTS assay [PMID: 27776325]
SW1573 IC50 > 10 μg/mL Cytotoxicity against human SW1573 cells after 3 days by MTT assay [PMID: 11421746]

17 records · Scroll to view more

Luteoloside Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Luteoloside from 3 published references. In vitro models include L. donovani promastigotes; Hela cells.

Luteoloside In Vitro Studies

The Luteoloside studies in L. donovani promastigotes reported that cynaroside checked parasites in the G0/G1 phase of the cell cycle and induced ROS generation. In Hela cells treated with Luteoloside for 48 h, the half maximal inhibitory concentration for cell growth was 18.9 μM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell Cycle Effects in Parasites

Cell-based study · L. donovani promastigotes [1]

L. donovani promastigotes were cultured with different concentrations of cynaroside. Cynaroside checked parasites in the G0/G1 phase of the cell cycle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell cycleReported result Cynaroside checks the parasites in G0/G1 phase of cell cycle[1]

Literature-Reported Treatment Conditions

Exposure duration
48 h at 22°C
Method
cultured
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Luteoloside; Compound label in the paper: Cynaroside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Study of cell cycle of promastigotes (S20, S22); Figure 3 legend (S73, S74)

cell cycle: cell cycle; comparator: absence and presence of different concentrations of cynaroside — Figure 3 legend (S73, S74)

Growth inhibition in Hela cells

Cell-based study · Hela cells [2]

Hela cells received fresh media containing various doses of Luteoloside for 48 h. The half maximal inhibitory concentration for cell growth was 18.9 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell growth was determined using cell counting kit-8.IC50 48 h: IC50 = 18.9 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
3.13, 6.25, 12.5, 25, 50, 100, and 200 μM
Exposure duration
48 h
Method
fresh media containing various doses of luteoloside
Vehicle
dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: Luteoloside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Luteoloside Inhibits Proliferation and Alters Cell Morphology of Hela Cells (S3); 4. Material and Methods > 4.1. Cell Culture and Reagents (S66); 4. Material and Methods > 4.2. Cell Viability Assay (S68, S69, S71); Figure 1 legend (S121, S122)

Cell growth was determined using cell counting kit-8.: Cell growth was determined using cell counting kit-8.; comparator: media containing 0.1% DMSO — 2. Results > 2.1. Luteoloside Inhibits Proliferation and Alters Cell Morphology of Hela Cells (S3); Figure 1 legend (S122)

ROS Generation in Parasites

Cell-based study · L. donovani promastigotes [1]

L. donovani promastigotes were incubated with cynaroside. Cynaroside induced ROS generation in the parasites.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ROS generationReported result Cynaroside induced ROS generation in parasites[1]

Literature-Reported Treatment Conditions

Exposure duration
48 h
Method
incubated
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Luteoloside; Compound label in the paper: Cynaroside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Figure 4 legend (S75)

ROS generation: ROS generation — Figure 4 legend (S75)

Luteoloside In Vivo Studies

In the male BALB/c-nu/nu subcutaneous model, Luteoloside was administered at 2 mg/kg body weight for 4 weeks. The compound effect was isolated by comparison with control tumor volume and weight, with a tumor-weight inhibition rate of 53.1%. [3]

Tumor weight inhibition in a subcutaneous model

Animal study · male BALB/c-nu/nu, 6 weeks old; subcutaneous model; ten per group [3]

The second group of animals received luteoloside (2 mg/kg body weight) in vehicle, respectively, for 4 weeks. The luteoloside treatment significantly inhibited the growth of the xenograft, with inhibition rates (versus the control weight of the tumors) of 53.1%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the tumors were weighed immediately after dissectiontumor weight 53.1%[3]

Conditions shared by the study groups

Treatment course
Two weeks after the cells were injected; for 4 weeks
Vehicle
vehicle
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Luteoloside 2 mg/kg body weightThe first group received only 0.2 ml of vehicle material by gavage daily and served as a control group.inhibition rates (versus the control weight of the tumors) of 53.1%[3]
Luteoloside 2 mg/kg body weight
Model: male BALB/c-nu/nu, 6 weeks old; subcutaneous model; ten per group
Reported limits: Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Luteoloside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Xenograft Model and Treatments (S26, S27, S28, S29, S30, S33); Results > Luteoloside Inhibits in vivo Proliferation and Metastasis of HCC Cells (S94)

the tumors were weighed immediately after dissection: the tumors were weighed immediately after dissection; comparator: The first group received only 0.2 ml of vehicle material by gavage daily and served as a control group. — Materials and Methods > Xenograft Model and Treatments (S33); Results > Luteoloside Inhibits in vivo Proliferation and Metastasis of HCC Cells (S94)

Luteoloside 2 mg/kg body weight · Materials and Methods > Xenograft Model and Treatments (S28, S30); Results > Luteoloside Inhibits in vivo Proliferation and Metastasis of HCC Cells (S94)

Specifications

Manufacturer Adooq Bioscience
CAS Number 5373-11-5
Formula C21H20O11
Molecular Weight 448.38
Synonyms Glucoluteolin; Cinaroside
SMILES
C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (176.19 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Luteoloside Research References

  1. [1] Tabrez S, Rahman F, Ali R, et al. Cynaroside inhibits Leishmania donovani UDP-galactopyranose mutase and induces reactive oxygen species to exert antileishmanial response. Biosci Rep (2021). PMID: 33367614 DOI: 10.1042/BSR20203857 Source material
  2. [2] Shao J, Wang C, Li L, et al. Luteoloside Inhibits Proliferation and Promotes Intrinsic and Extrinsic Pathway-Mediated Apoptosis Involving MAPK and mTOR Signaling Pathways in Human Cervical Cancer Cells. Int J Mol Sci (2018). PMID: 29874795 DOI: 10.3390/ijms19061664 Source material
  3. [3] Fan SH, Wang YY, Lu J, et al. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS One (2014). PMID: 24587153 DOI: 10.1371/journal.pone.0089961 Source material

Added to your cart

View Cart Checkout
Loading...